Peptide Cycling in Bodybuilding

Your Receptors Are Getting Tired

Think about the first time you took a high-stim pre-workout. It felt like you could run through a wall. Six weeks later, you're double-scooping just to feel normal. Your body adapted. Lifters assume the same principle applies to many of the peptides used for physique goals, and the usual name for it is receptor downregulation, or desensitization.

When you introduce a peptide like Ipamorelin or GHRP-2, it knocks on the door of a specific receptor, in this case the ghrelin receptor (GHSR), to trigger a pulse of growth hormone. Keep knocking and the cell may pull the receptor from its surface. In cell culture, the ghrelin receptor leaves the surface within about 20 minutes of exposure to ghrelin and takes around six hours to come back. This is tachyphylaxis, a fancy word for diminishing returns.

The idea behind cycling is giving your receptors a break so they can re-sensitize. It's the biological equivalent of a deload week. Whether people actually need that break depends on which kind of peptide you mean.

Growth Hormone Secretagogues: The Classic Cycle

This is where cycling comes up most. Peptides that work by stimulating your pituitary gland to release growth hormone (GH) are the usual examples of receptor desensitization. This category includes:

• GHRHs (Growth Hormone Releasing Hormones): CJC-1295 (both with and without DAC), Sermorelin, Tesamorelin
• GHRPs (Growth Hormone Releasing Peptides) / Ghrelin Mimetics: GHRP-6, GHRP-2, Ipamorelin, Hexarelin

Forum guides often say a constant signal is counterproductive for all of these compounds, because the pituitary needs a pulsatile signal, not a firehose. The human studies split along the two groups.

For the ghrelin mimetics, hexarelin has the best data. In 12 healthy older adults on twice-daily subcutaneous hexarelin for 16 weeks, the GH response fell by about 45%, then returned to baseline 4 weeks after stopping. In short children on intranasal hexarelin, the response roughly halved within a week and then held steady for 6 months. Users report a similar fade. We found no comparable long-term human data for the other GHRPs.

For the GHRH analogues, the data point the other way. In five healthy men given a continuous intravenous GHRH infusion for 14 days, GH kept coming in pulses and the response to a large test dose wasn't blunted. A 2006 study of CJC-1295 with DAC, which stimulates GHRH receptors for days, found GH still came in normal pulses a week after one injection. The case for cycling GHRH analogues rests mostly on user experience.

The Two Main Cycling Strategies

1. Time On / Time Off: This is the macro-level strategy. Users run a cycle for a set period, then take a break, most commonly an 8-12 week "on-cycle" followed by a 4-8 week "off-cycle." No trial has tested that schedule. The closest human evidence is the hexarelin study, where 4 weeks off restored the GH response.

2. Pulsing (5 Days On / 2 Days Off): This is a micro-strategy used during the on-cycle: two consecutive days off per week (usually the weekend). It's the schedule users describe most for CJC-1295 without DAC plus ipamorelin, and they credit it with keeping a cycle effective. We found no study testing it. In cell culture the ghrelin receptor recovered within hours, so the mechanism alone doesn't explain why a two-day gap would matter.

Example Cycles: Putting It Together

These frameworks come from forum guides and vendor material refined in the bodybuilding community over years of trial and error. None has been tested against continuous use, and none is a recommendation.

GLP-1 Agonists: The Exception to the Rule

Then there are semaglutide and tirzepatide, prescription medicines approved for weight management as Wegovy and Zepbound. Some lifters use them to get lean for shows: in a STEP 1 trial subset, adults with obesity on semaglutide 2.4 mg weekly lost 17.3% of body weight over 68 weeks. Research-use vials aren't equivalent to the approved products, and these drugs aren't cycled like a GHS.

These peptides work on the GLP-1 (and GIP, for Tirzepatide) receptors to control blood sugar and slow gastric emptying. The labeled protocols involve titrating the dose upwards over months. As of October 2026, the Wegovy label starts at 0.25 mg once weekly for 4 weeks, then steps up every 4 weeks to a usual maintenance dose of 2.4 mg, with 7.2 mg allowed after at least 4 weeks on 2.4 mg.

Two things explain the different approach:

1. Side Effect Management: The label uses the slow escalation to reduce nausea and other gut side effects.
2. Continuous Signal: The goal here is a continuous signal for appetite control. Users don't want their appetite returning for two days every weekend while they're deep in a deficit.

The "cycle" for a GLP-1 agonist isn't 8 weeks on, 4 weeks off. Lifters treat the entire contest prep or fat-loss phase as the cycle. Stopping has a cost: in the STEP 1 extension, people who came off semaglutide regained about two-thirds of the lost weight within a year. That trial studied adults with obesity, not lean athletes. Our page on long-term peptide use in bodybuilding covers what happens when these drugs run for years.

What We Still Don't Know

Cycling is near-universal advice for growth hormone secretagogues, but the evidence behind it is thin. The hexarelin data support tolerance that builds within weeks and fades after a break. No study has compared 5-on/2-off or an 8-12 week cycle with continuous dosing for any of these peptides. Trials also haven't shown that the extra GH turns into fat loss; see ipamorelin's fat-loss evidence and CJC-1295 for fat loss.

For other categories, the logic changes. Users describe healing peptides like BPC-157 as something used for a specific timeframe and then stopped. GLP-1 medicines are run continuously throughout a dieting phase rather than pulsed. The open question there is weight regain, not receptor fatigue.